Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1495-1502

  Manca, Antonella ^a   Sini, Maria Cristina ^a   Izzo, Francesco ^b   Ascierto, Paolo A ^b   Tatangelo, Fabiana ^b   Botti, Gerardo ^b   Gentilcore, Giusy ^b   Capone, Marilena ^b   Mozzillo, Nicola ^b   Rozzo, Carla ^a   Cossu, Antonio ^c   Tanda, Francesco ^d   Palmieri, Giuseppe ^a  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Hospital University Health Unit (AOU)   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Arginine deiminase; Argininosuccinate synthetase; Expression analysis; In vitro proliferation test; Malignant melanoma

Indexed keywords

ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; ORNITHINE CARBAMOYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER CELL CARCINOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TISSUE SECTION;

ANTINEOPLASTIC AGENTS; ARGININOSUCCINATE SYNTHASE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; MELANOMA; ORNITHINE CARBAMOYLTRANSFERASE;

EID: 79954473064     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1220     Document Type: Article

References (29)

1. Morris SM Jr: Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22: 87-105, 2002.
2. Wu G and Morris SM Jr: Arginine metabolism: nitric oxide and beyond. Biochem J 336: 1-17, 1998. (Pubitemid 28532555)
3. Tapiero H, Mathe G, Couvreur P and Tew KD: Arginine. Biomed Pharmacother 56: 439-445, 2002.
4. Husson A, Brasse-Lagnel C, Fairand A, Renouf S and Lavoinne A: Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 270: 1887-1899, 2003.
5. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T and Szlosarek PW: Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126: 2762-2772, 2010.
6. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT and Feun LG: Arginine deprivation, autophasy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 10: 405-412, 2010.
7. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH and Leung YC: Pegylated recombinant human arginase (rhArg-peg 5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67: 309-317, 2007. (Pubitemid 46142789)
8. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH and Leung YC: Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 277: 91-100, 2009.
9. Sugimura K, Ohno T, Kusuyama T and Azuma I: High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res 2: 191-196, 1992.
10. Gong H, Zolzer F, von Recklinghausen G, Rössler J, Breit S, Havers W, Fotsis T and Schweigerer L: Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 261: 10-14, 1999. (Pubitemid 29371610)
11. Wheatley DN: Controlling cancer by restricting arginine availability: Arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 15: 825-833, 2004.
12. Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA: Pegylated arginine deiminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62: 5443-5450, 2002.
13. Feun L and Savaraj N: Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 15: 815-822, 2006.
14. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C and Curley SA: Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22: 1815-1822, 2004.
15. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG and Logan TF: Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23: 7660-7668, 2005. (Pubitemid 46291831)
16. Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F and Korba BE: Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 22: 86-91, 2007. (Pubitemid 44953422)
17. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100: 826-833, 2004. (Pubitemid 38176863)
18. Casula C, Muggiano A, Cossu A, Budroni M, Caracò C, Ascierto PA, Pagani E, Stanganelli I, Canzanella S, Sini MC, Palomba G, The Italian Melanoma Intergroup (IMI) and Palmieri G: Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 9: 352, 2009.
19. Pisano M, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Pagnan G, Ponzoni M and Rozzo C: Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Molecular Cancer 6: 8, 2007.
20. Pisano M, Pagnan G, Dettori MA, Cossu S, Caffa I, Sassu I, Emionite L, Fabbri D, Cilli M, Pastorino F, Palmieri G, Delogu G, Ponzoni M and Rozzo C: Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol Cancer 9: 137, 2010.
21. Kueng W, Silber E and Eppenberger U: Quantification of cells cultured on 96-well plates. Anal Biochem 182: 16-19, 1989. (Pubitemid 19251274)
22. Sini MC, Manca A, Cossu A, Budroni M, Botti G, Ascierto PA, Cremona F, Muggiano A, D'Atri S, Casula M, Baldinu P, Palomba G, Lissia A, Tanda F and Palmieri G: Molecular alterations at chromosome 9p21 in melanocytic nevi and melanoma Br J Dermatol 158: 243-250, 2008.
23. Agarwala SS and O'Day SJ: Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat Rev 37: 133-142, 2010.
24. Flaherty KT and McArthur G: BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116: 4902-4913, 2010.
25. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA and Izzo F: Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28: 2220-2226, 2010.
26. Summar ML: Urea cycle disorders overview. In: Pagon RA, Bird TC, Dolan CR, Stephens K (eds). Gene Reviews [Internet]. Seattle: University of Washington, Seattle; 1993-2003 Apr 29 [updated 2005 Aug 11].
27. You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM and Feun L: The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun 394: 760-766, 2010.
28. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ and Bold RJ: Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123: 1950-1955, 2008.
29. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK and Min BH: Renal cell carcinoma does not express arginino-succinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120: 897-905, 2007.